HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $131,568,000 | +10.2% | 3,444,190 | +4.1% | 0.16% | +21.3% |
| Q2 2023 | $119,368,000 | -2.3% | 3,309,355 | +3.4% | 0.14% | -6.2% |
| Q1 2023 | $122,226,000 | -17.5% | 3,200,481 | +22.8% | 0.14% | -17.1% |
| Q4 2022 | $148,239,000 | +46.7% | 2,605,261 | +2.0% | 0.18% | +41.1% |
| Q3 2022 | $101,065,000 | -8.9% | 2,554,967 | +1.4% | 0.12% | -0.8% |
| Q2 2022 | $110,903,000 | +12.4% | 2,520,531 | +1.9% | 0.12% | +66.7% |
| Q1 2022 | $98,689,000 | -20.1% | 2,474,646 | -19.5% | 0.08% | -27.2% |
| Q4 2021 | $123,564,000 | +1.5% | 3,072,956 | +2.7% | 0.10% | -1.0% |
| Q3 2021 | $121,717,000 | -8.9% | 2,992,067 | +1.7% | 0.10% | -5.5% |
| Q2 2021 | $133,593,000 | +45.0% | 2,941,938 | +33.1% | 0.11% | -15.4% |
| Q1 2021 | $92,138,000 | -6.9% | 2,210,060 | -4.7% | 0.13% | -10.3% |
| Q4 2020 | $99,004,000 | +75.5% | 2,318,052 | +8.0% | 0.14% | +51.0% |
| Q3 2020 | $56,410,000 | +791.9% | 2,146,504 | +809.7% | 0.10% | +772.7% |
| Q2 2020 | $6,325,000 | +49.9% | 235,949 | +0.6% | 0.01% | +22.2% |
| Q1 2020 | $4,220,000 | +3.5% | 234,564 | +2.0% | 0.01% | +50.0% |
| Q4 2019 | $4,078,000 | +14.3% | 230,000 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $3,567,000 | -69.9% | 230,000 | -66.7% | 0.01% | -14.3% |
| Q2 2019 | $11,853,000 | +84.1% | 690,000 | +72.5% | 0.01% | -36.4% |
| Q1 2019 | $6,440,000 | -12.0% | 400,000 | -20.0% | 0.01% | -21.4% |
| Q4 2018 | $7,315,000 | -19.5% | 500,000 | 0.0% | 0.01% | -6.7% |
| Q3 2018 | $9,085,000 | +7.7% | 500,000 | 0.0% | 0.02% | 0.0% |
| Q2 2018 | $8,435,000 | -13.9% | 500,000 | 0.0% | 0.02% | -16.7% |
| Q1 2018 | $9,795,000 | -4.1% | 500,000 | -0.8% | 0.02% | 0.0% |
| Q4 2017 | $10,213,000 | +17.6% | 504,100 | +0.8% | 0.02% | +12.5% |
| Q3 2017 | $8,685,000 | +35.5% | 500,000 | 0.0% | 0.02% | +33.3% |
| Q2 2017 | $6,410,000 | +7.5% | 500,000 | +8.7% | 0.01% | +9.1% |
| Q1 2017 | $5,962,000 | +31.2% | 460,000 | 0.0% | 0.01% | +22.2% |
| Q4 2016 | $4,545,000 | +23.4% | 460,000 | +50.9% | 0.01% | +28.6% |
| Q3 2016 | $3,682,000 | -30.0% | 304,800 | -50.0% | 0.01% | +40.0% |
| Q2 2016 | $5,260,000 | +82.3% | 609,600 | +100.0% | 0.01% | -16.7% |
| Q1 2016 | $2,886,000 | – | 304,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |